[Immunoscintigraphy with 99mTc marked melanoma antibody in patients with malignant melanoma].
In 38 patients with malignant melanoma 44 radioimmunoscintigraphies (RIS) with 99mTc labeled F(ab')2 fragments of an anti-melanoma monoclonal antibody (225.28S, Tecnemab-K, Sorin Biomedica) have been performed. No side effects have been observed even in the patients with repeated RIS. Overall 81% (35/43) of all lesions were detected by imaging and 9 lesions have been previously unknown. Sensitivity and specificity was highest for lymphnode metastases with 100% each. Poor imaging was observed in lung and mediastinal metastases (2/7) as well as small skin metastases. RIS has to be studied for its clinical value in staging of lymphnode metastases preoperatively in patients undergoing regional lymphnode dissection.
M
M
Rentsch
T
T
Cerny
J
J
Richner
K W
KW
Brunner
H
H
Rösler
B
B
Nachbur
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D008545:Melanoma / Q000000981:diagnostic imaging*; D058950:Melanoma-Specific Antigens; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000276:immunology*; D011877:Radionuclide Imaging; D012878:Skin Neoplasms / Q000000981:diagnostic imaging*; D013667:Technetium
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D013667:Technetium
Immunszintigraphie mit einem 99mTc markierten Melanomantikörper bei Patienten mit malignem Melanom.